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Background: Neonatal bilateral endogenous endophthalmitis is rare and often results in devastating visual outcome.
Findings: An 18-day-old neonate presented with whitening of the cornea in the left eye. The child was examined
under anesthesia, and a diagnosis of bilateral endogenous endophthalmitis was made. Vitreous biopsy from the left
eye showed no growth. Blood samples showed growth of Staphylococcus epidermidis which was multidrug resistant
(including vancomycin) but sensitive to piperacillin-tazobactam. The patient was managed with bilateral intravitreal
injections of piperacillin-tazobactam and systemic cefpodoxime. Systemic and topical antibiotics were given for 3 and
8 weeks, respectively, and infection was controlled. At 2-year follow-up, the right eye is fixing and following to light
with clear view of the fundus and the left eye has a clear cornea with red glow of the fundus.
Conclusions: Vancomycin-resistant S. epidermidis may be a cause of endogenous endophthalmitis. Intravitreal
piperacillin-tazobactam and systemic cefpodoxime were used to eliminate the infection in this neonate.
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Background
Endogenous endophthalmitis in the pediatric population
is rare and is usually associated with poor visual outcomes.
Endogenous endophthalmitis in neonates constitutes 0.1%
to 4% of all endogenous endophthalmitis cases [1-3], with
the highest incidence of cases reported in India and the
lowest in the United States. Gram-positive organisms are
causative in 30% to 35% of endogenous endophthalmitis
[4,5]. Potential risk factors [6,7] for neonatal endogenous
endophthalmitis are immune-compromised status, low
birth weight (<1,500 g), bacteremia, prematurity, blood
transfusion, respiratory infection, perinatal infection, hos-
pital admission, intravenous catheters, and retinopathy of
prematurity. Vancomycin resistance among enterococci,
coagulase-negative Staphylococci, and Bacillus is being in-
creasingly reported [8] in ocular infections. Herein, we* Correspondence: relhan_nidhi@yahoo.co.in
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multidrug-resistant gram-positive cocci in a neonate of
age 18 days.
Case report
An 18-day full-term male baby, born by normal vaginal
delivery in rural India, presented with redness in the left
eye for 1 day. There was no history of maternal fever, va-
ginal purulent discharge, or any complication before,
during, or after birth. On initial examination, the child
looked active, the right eye lacked a red reflex, and the
left eye exhibited leukocoria. Echography showed an at-
tached retina in both eyes without any evidence of intra-
ocular calcification or mass lesion (Figure 1a,b). The left
eye exhibited moderate-intensity opacities diffusely in
the vitreous cavity. Computed tomography scan of the
orbits could not be obtained due to financial limitation.
On the day of presentation, after discussing the possibil-
ity of intraocular malignancy with the parents and
obtaining written informed consent, the child was exam-
ined under anesthesia. The right eye had a clear cornea,
well-formed anterior chamber, non-dilating pupil, iris vas-
cular congestion, clear lens, and vitritis with no fundusn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Ultrasound B-scan and clinical photographs of both eyes taken under operating microscope at presentation. Ultrasound B-scan shows
attached retina in both eyes with clear vitreous cavity in the right eye (a) and echogenic shadows in the left vitreous cavity (b). Clinical photographs
taken under operating microscope shows clear cornea in the right eye (c) and diffuse circumciliary congestion with opaque cornea obscuring any further
details in the left eye (d).
Table 1 Treatment details of the patient
Day of presentation
(age in days)
Events
1 (18th day of life) Surgical treatment
Left eye - anterior chamber wash + vitreous
biopsy
Both eyes - IOAB (V + C + D)a
Topical treatment in both eyes - ciprofloxacin
0.3% four times a day, prednisolone acetate
1% every 3 h, and atropine 1% eye ointment
at nighttimeb
Systemic treatment - intravenous cefpodoxime
by a pediatricianc
3 (21st day of life) Both eyes - IOAB (V + C + D)a
8 (26th day of life) Both eyes - IOAB (P/T + D)d
13 (31st day of life) Left eye - IOAB (P/T + D)d
aIOAB (V + C + D) - intravitreal antibiotics (vancomycin 0.5 mg/.05 ml + ceftazidime
1 mg/0.05 ml) and dexamethasone (200 μg/0.05 ml); btopical antibiotics were
continued for 8 weeks (until resolution of all active inflammation); csystemic
antibiotics were given for 3 weeks; dIOAB (P/T + D) - intravitreal antibiotics
[piperacillin- tazobactam (112.5 μg/0.05 ml)] and dexamethasone (200 μg/0.05 ml).
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(deep and diffuse) was seen with diffuse corneal edema
obscuring all further details (Figure 1d). A diagnosis of en-
dogenous endophthalmitis was made. In the left eye, the
anterior chamber was irrigated with saline through a sin-
gle limbal paracentesis but it did not alter the corneal ap-
pearance which remained opaque white. A vitreous biopsy
could only be performed in the left eye with a 23 G vitre-
ous cutter at 0.5 mm from the limbus because of no view
to the posterior segment. The sclerotomy port was sutured
with 7-0 vicryl suture. Intravitreal antibiotics (vancomycin
0.5 mg/.05 ml + ceftazidime 1 mg/0.05 ml) and dexa-
methasone (200 μg/0.05 ml) were injected in both eyes
with separate 29 G needles at 0.5 mm from the limbus
since there were no fungal filaments on smear evaluation
of the vitreous. Details of treatment are mentioned in
Table 1.
Vitreous biopsy was negative for any growth while the
blood culture showed gram-positive organisms (Staphylo-
coccus epidermidis) which were resistant to vancomycin,
amoxicillin, kanamycin, cephalothin, and erythromycin by
the Kirby-Bauer disk diffusion method. Urine cultures of
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of the mother showed no growth. The isolates were sensi-
tive to piperacillin-tazobactam (112.5 μg/0.05 ml) which
was administered intravitreally as mentioned in Table 1. In
the subsequent week, the child’s right pupil was mid-
dilated with a good view of the disk and macula while the
left cornea continued to be opaque with decreased signs
of ocular inflammation.
At 12 months of follow-up (Figure 2), no active in-
flammation was seen in either eye. The right eye fixed
and followed light. The corneal whitening in the left eye
has resolved. Twenty one months after presentation,
cataract surgery was performed on the left eye due to
subsequent cataract formation. At the 2-year follow-up,
the right eye has good visual function with fix-and-
follow vision and a good view of the posterior segment.
The left eye is pseudophakic with a good red reflex and
has a clear cornea.
Discussion
Vancomycin resistance among gram-positive bacterial
endophthalmitis has become a major global health issue
[9]. Vancomycin - a glycopeptide - is the drug of choice
for methicillin-resistant coagulase-negative Staphylococcus
and methicillin-resistant Staphylococcus aureus (MRSA)
infections [10,11]. Biofilm formation [12] and alteration of
binding sites of drug [13] are the mechanisms of acquiring
resistance to vancomycin. These resistant traits are then
selected for in the presence of vancomycin. The
Endophthalmitis Vitrectomy Study in 1996 reported the
vancomycin sensitivity of gram-positive organisms to be
100%. A few reports of vancomycin resistance among
Bacillus, Enterococcus, and Staphylococcus species causing
endophthalmitis have been published recently [11,13,14].
In this patient, the organism was sensitive to piperacillin-
tazobactam, cefotaxime, doxycycline, clarithromycin,
cefixime, and gentamycin. Piperacillin-tazobactam is a
combination of beta-lactam antibiotic with beta-lactamase
inhibitor in a ratio of 8:1 (piperacillin/tazobactam) and has
broad antibacterial activity against gram-positive and gram-
negative pathogens [9,15]. Endogenous endophthalmitis isFigure 2 Clinical picture showing resolved endophthalmitis
with clear corneal reflex in both eyes at 1 year follow-up.associated with poor anatomical and visual outcomes. In a
study of 26 neonates [6] with endogenous endophthalmi-
tis, 22 out of 26 cases (84.61%) became phthisical.
Khera et al. [13] reported a single case of endogenous
endophthalmitis, caused by vancomycin-resistant gram-
positive cocci, in an adolescent resulting in enucleation.
In our case, the child had a better outcome with
complete resolution of endophthalmitis in both eyes
and achieved fixing and following in the right eye.
Maternal infections, sepsis during childbirth, low birth
weight, etc. are the reported predisposing factors for
neonatal endogenous endophthalmitis. In the present case,
detailed history (both mother and child) did not reveal the
predisposing factor. The fact that the child was born by a
vaginal delivery in the rural India may raise the possibility
of infection in perinatal or postnatal period.
In this case, no immunological workup to rule out im-
paired immunity was done. However, the child responded
to the antibiotics well without any further recurrence or
disease. Another limitation was that antibiotic resistance
was assayed by disk diffusion only and not by minimum
inhibitory concentration (MIC) because this assay was not
available. Additionally, cultures were positive only from
blood and not intraocular fluid; however, the subsequent
response to treatment supports our clinical impression
that the child’s bacteremia was the cause of endophthalmi-
tis, implicating multidrug-resistant S. epidermidis as the
target pathogen. To the best of our knowledge, this is the
first reported case of vancomycin-resistant bilateral
endogenous endophthalmitis in a neonate with good out-
comes. This report emphasizes the need of early manage-
ment including intravitreal antibiotics guided by culture
sensitivities which can result in a favorable outcome.Conclusion
In conclusion, early recognition of antibiotic resistance
and treatment with appropriate antibiotics (as in our
case with piperacillin-tazobactam) were associated with
resolution of infection. Ocular and extraocular culture
and sensitivities should be obtained as early as possible
to isolate the causative organism and best chose an
appropriate therapy. Appropriate early intervention can
result in favorable outcome.Consent
The written informed consent from the parents of child
was taken before initiating the treatment. IRB of our
institute does not require approval to write case report
up to 3 cases.
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